



FEATURED OPTIONS RADAR REPORT



Bullish Bet on BioMarin Data

Ticker/Price: BMRN (\$77.70)

Analysis:

BioMarin (BMRN) large trade on 12/10 sold 3500 January \$70 puts to buy 2600 of the \$80/\$95 call spreads, and the \$80 calls already with 2700X in OI. BMRN has seen some action in April \$85 and \$100 calls since September and also January 2022 \$90 puts were sold to open 880X. BMRN has been a laggard in 2021 among Biotech names and has not been able to recover much since the big gap down move in August following a CRL for Valoctocogene Roxaparvovec gene therapy for Severe Hemophilia A and pushed back a potential approval to 2022. BMRN will have a PDUFA on 8-20-2021 for Vosoritide to treat children with Achondroplasia. On a longer term chart shares are back to a familiar support level since 2016 and looking to form another bottom. The \$13.75B company now trades 7.4X Sales with revenues seen rising 8.8% this year and 4.3% in 2021. BMRN at Evercore last week noted it will share to-line 1 year results from 134 subjects in Phase 3 study of ROCTAVIAN gene therapy for the treatment of hemophilia A in early 2021. Analysts have an average target of \$110 and short interest at 6.5% of the float has risen 17% Q/Q to multi-year highs. On 11/3 Piper remained a buyer of BMRN shares expecting 2H 2021 approval and has a \$123 target. BMRN has also lagged ahead of Kuvan's 2021 patent cliff, so the pipeline success is very important for shares. Hedge Fund ownership fell 14% in Q3 filings, Baker Brothers a top holder as its 7th largest position.

Hawk Vision:



Hawk's Perspective: BMRN clearly an event-driven play at this point though have plenty of concerns with weak price action, rising short interest, and declining institutional ownership, so not an overly confident one, but could also quickly see \$100+ on positive developments.

Confidence Ranking: \$\$